Welcome to our dedicated page for Avita Medical SEC filings (Ticker: RCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AVITA Medical's SEC filings document its therapeutic acute wound-care business, RECELL-related commercial activity, operating results, capital structure, and corporate governance. Form 8-K reports include quarterly and annual financial results, material definitive agreements, credit-facility amendments and refinancing activity, leadership appointments, and board-structure changes.
Proxy materials describe annual meeting matters such as director elections, auditor ratification, non-executive director compensation, equity-award approvals, and governance requirements tied to the company's U.S. listing and ASX-related matters. The filings also provide formal disclosure around debt obligations, subsidiary guarantees, shareholder voting items, executive compensation arrangements, and risk areas affecting AVITA Medical's wound-care operations.
AVITA Medical, Inc. director Suzanne Crowe reported equity awards granted as part of her compensation. She received 22,214 restricted stock units, each representing one share of common stock, which vest 12 months after the January 20, 2026 grant date, subject to previously obtained stockholder approval. She was also granted 16,133 stock options to buy common stock at an exercise price of $3.77 per share, exercisable until January 20, 2036. Following these awards, her direct holdings total 69,148 shares of common stock, which include unvested RSUs and 22,990 CHESS Depositary Interests that translate into 4,598 of these shares.
AVITA Medical, Inc. director Jan Stern Reed reported equity awards consisting of restricted stock units and options. Reed received 22,214 restricted stock units, each representing one share of common stock, that vest 12 months after the January 20, 2026 grant date and were subject to stockholder approval obtained on June 3, 2026.
On the same grant date, Reed was also granted 16,133 stock options to buy 16,133 shares of common stock at an exercise price of $3.77 per share, with an expiration date of January 20, 2036, also approved by stockholders on June 3, 2026. Following the equity award, Reed directly holds 73,225 shares of common stock, including unvested RSUs.
AVITA Medical, Inc. reported results of its 2026 annual stockholder meeting held by webcast. Of 30,776,689 common shares outstanding as of April 9, 2026, holders of 15,592,447 shares were represented, meeting quorum requirements.
Stockholders elected all seven director nominees and ratified Grant Thornton LLP as independent auditor for the year ending December 31, 2026. They approved increasing the non-executive directors’ aggregate annual cash fee pool from US$750,000 to US$900,000 and backed annual equity grants of restricted stock units and stock options to non-executive directors.
Initial equity grants to directors Michael Tarnoff and Joseph Woody were approved, along with an advisory vote in favor of named executive officer compensation and a preference for holding say-on-pay votes every one year. Stockholders also approved issuing warrants covering up to 650,000 shares to Perceptive Credit Holdings V, LP under an existing credit agreement and authorized the potential issuance of additional equity securities of up to 10% of issued capital under ASX Listing Rule 7.1A.
AVITA Medical, Inc. director Woody Joseph Fralin bought a total of 20,000 shares of Common Stock in open-market transactions. The purchases occurred on June 1 and 2 at prices between $4.18 and $4.34 per share, bringing his direct holdings to 20,000 shares.
AVITA Medical, Inc. CFO David D. O'Toole acquired 5,000 shares of common stock in a Form 4 transaction. The shares were obtained through the company’s Employee Share Purchase Plan at $3.0515 per share, based on an 85% discount to the December 1, 2025 closing price. Following this acquisition, he directly holds 150,927 shares, including unvested RSUs.
AVITA Medical, Inc. President and CEO Vance Cary Guy acquired 5,000 shares of common stock through the company’s Employee Share Purchase Plan. The shares were purchased at $3.0515 per share, equal to 85% of the closing price on December 1, 2025, for the ESPP period that ran through May 31, 2026.
After this transaction, he holds 40,771 shares directly, a figure that includes unvested restricted stock units. The acquisition is classified as a grant or award and was exempt under Rule 16b-3(d) and Rule 16b-3(c), indicating a compensation-related, routine purchase rather than an open-market trade.
AVITA Medical, Inc. CFO David D. O'Toole reported an open-market purchase of 2,000 shares of common stock at a price of $4.26 per share. Following this transaction, he directly holds 145,927 shares, which the disclosure states include unvested restricted stock units.
AVITA Medical, Inc. CFO David D. O'Toole reported an open-market purchase of common stock. He bought 2,000 shares at $4.24 per share, increasing his direct holdings to 143,927 shares. The reported total includes unvested restricted stock units, indicating both vested and unvested equity exposure.
AVITA Medical, Inc. reported first-quarter 2026 revenue of $19.3 million, up modestly from $18.5 million a year earlier, driven mainly by increased contributions from Cohealyx and RECELL GO alongside stable RECELL sales.
The company posted a net loss of $10.6 million, an improvement from a $13.9 million loss in the prior-year quarter, as operating expenses declined across sales and marketing, general and administrative, and research and development. Cash, cash equivalents, and marketable securities totaled $14.3 million as of March 31, 2026, while operating activities used $10.1 million of cash in the quarter.
AVITA refinanced its prior debt with a new five-year senior secured credit facility from Perceptive Advisors, drawing $50.0 million and receiving about $6.0 million in net proceeds after repayment of the previous credit agreement and fees. The fair value of the loan facility was $46.1 million at quarter-end, and the company reported a stockholders’ deficit of $23.2 million with an accumulated deficit of $419.0 million.
Management concluded there is “substantial doubt” about AVITA’s ability to continue as a going concern over the next twelve months due to recurring losses, negative operating cash flows, and debt repayment obligations. As a result, the long-term portion of the credit facility is classified as a current liability. The company is evaluating options such as accessing an additional $10.0 million under the facility, subject to net revenue requirements, or raising equity financing.
After quarter-end, AVITA entered a ten-year agreement with BARDA with a total potential value of up to $25.5 million, including about $3.97 million in expected access and readiness fees over the term and additional procurement options. The Board also confirmed Cary Vance as President and Chief Executive Officer and appointed Jan Stern Reed as Chair of the Board.
AVITA Medical reported first quarter 2026 revenue of approximately $19.3 million, up 4% year-over-year and about 10% sequentially, driven by Cohealyx and improved RECELL utilization as reimbursement normalizes. Gross profit margin was 81.7%, while operating expenses fell 11% to $24.5 million following cost optimization initiatives.
The company recorded a net loss of $10.6 million, or $0.35 per share, improving from a $13.9 million loss, or $0.53 per share, a year earlier. AVITA ended the quarter with $14.3 million in cash and marketable securities and net cash use of about $9.9 million, which management expects to decrease significantly in the second quarter.
The company reaffirmed full-year 2026 revenue guidance of $80 million to $85 million, implying growth of roughly 12% to 19% over 2025. AVITA also highlighted a 10-year BARDA agreement valued at up to $25.5 million, positive interim Cohealyx I clinical data, and new RECELL GO clearance in Australia and New Zealand.